Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Biofrontera (BFRI)
Marpai (MRAI)
Cingulate, Inc. (CING)
Stronghold Digital Mining, Inc. (SDIG)
Enfusion, Inc. (ENFN)
Portillos Inc. (PTLO)
Winc, Inc. (BEV)
The Vita Coco Company, Inc. (COCO)
P10, Inc. (PX)
Ventyx Biosciences, Inc. (VTYX)
Winc, Inc. (WBEV)
Runway Growth Finance Corp (RWAY)
Aris Water Solutions, Inc. (ARIS)
Minerva Surgical, Inc (UTRS)
Xilio Therapeutics, Inc. (XLO)
Informatica Inc. (INFA)
Arteris, Inc. (AIP)
Priced IPO
Mink Therapeutics, Inc. (INKT)
Paragon 28, Inc. (FNA)
Ihs Holding Limited (IHS)
Gitlab Inc. (GTLB)
Lucid Diagnostics, Inc. (LUCD)
Healthcare Triangle (HCTI)
AvidXchange (AVDX)
Cognition Therapeutics, Inc. (CGTX)
Isoplexis Corporation (ISO)
Pyxis Oncology, Inc. (PYXS)
Life Time Group Holdings, Inc. (LTH)
Theseus Pharmaceuticals, Inc. (THRX)
Tricon Residential (TCN)
Volcon (VLCN)
Nuvei (NVEI)
Tdcx, Inc. (TDCX)
First Watch Restaurant Group, Inc. (FWRG)
Exscientia Limited (EXAI)
Warby Parker (WRBY)
Olaplex Holdings Inc. (OLPX)
More companies

Theseus Pharmaceuticals, Inc. (THRX)

Sector - Healthcare

Price chart

+0.12%
Return from IPO

Company News

IPO Profile

About company

They are a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Their initial focus is on developing the next generation of tyrosine kinase inhibitors, or TKIs, and is rooted in the critical role that tyrosine kinases play in the development of cancer. Their goal is to develop “pan-variant” kinase inhibitors -- inhibitors that target all major cancer causing and drug resistance mutations in clinically significant protein kinases. Their lead product candidate, THE-630, is a pan-variant inhibitor of all major classes of activating and resistance mutations of the KIT kinase, or a pan-KIT inhibitor, for the treatment of gastrointestinal stromal tumors, or GIST, a type of cancer characterized by oncogenic activation of KIT. THE-630 is derived from intellectual property exclusively licensed to them by ARIAD Pharmaceuticals, Inc., or ARIAD. They plan to submit an Investigational New Drug, or IND, application to the U.S. Food and Drug Administration, or FDA, in the fourth quarter of 2021 for the evaluation of THE-630 in patients with advanced GIST whose disease has developed resistance to prior KIT-targeting therapies, and, if accepted, initiate a phase 1/2 dose escalation and expansion clinical trial.
Industry
Pharmaceutical Preparations
CEO CFO
-
Employees Founded
14 2017

Contacts

Address: 245 Main Street Cambridge, Massachusetts 02142

Telephone: (857) 400-9491

Web page: http://theseusrx.com

IPO information

First Trade Date 10/7/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 8.3
Shares Revised (MM) 10
Expected offer amount (MM) $124.5
Realized offer amount(MM) $160

Financial Data (last reporting year)

Market Cap (MM) $537.9
Revenues (MM) $0
Net Income (Loss) (MM) $-15.6

Voting

What do you think will happen with the THRX share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Jefferies

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Jefferies/ SVB Leerink/ Cantor
CO-Managers
Wedbush PacGrow

Sector: Healthcare

Tweets about $THRX

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats